[HTML][HTML] Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil… - Stem Cell Research & …, 2021 - Springer
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
[HTML][HTML] Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
JL Carter, K Hege, J Yang, HA Kalpage, Y Su… - Signal transduction and …, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
De novo acute myeloid leukemia: a population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) …
K Sasaki, F Ravandi, TM Kadia, CD DiNardo… - Cancer, 2021 - Wiley Online Library
Background Several important treatment and supportive care strategies have been
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …
Cancer metabolism: current understanding and therapies
JL Counihan, EA Grossman, DK Nomura - Chemical reviews, 2018 - ACS Publications
Dysregulation of cancer cell metabolism contributes to abnormal cell growth, the biological
end point of cancer. We review here numerous affected oncogenes and metabolic pathways …
end point of cancer. We review here numerous affected oncogenes and metabolic pathways …
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
ES Winer, RM Stone - Therapeutic advances in hematology, 2019 - journals.sagepub.com
Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by
rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While …
rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While …
[HTML][HTML] Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside
Despite impressive efforts invested in epigenetic research in the last 50 years, clinical
applications are still lacking. Only a few university hospital centers currently use epigenetic …
applications are still lacking. Only a few university hospital centers currently use epigenetic …
[HTML][HTML] Recent advances in the understanding and treatment of acute myeloid leukemia
J Watts, S Nimer - F1000Research, 2018 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …
has a poor prognosis. Recent advances in genomics and molecular biology have led to a …
Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
SK Mishra, SE Millman, L Zhang - Blood, 2023 - ashpublications.org
Metabolic rewiring and cellular reprogramming are trademarks of neoplastic initiation and
progression in acute myeloid leukemia (AML). Metabolic alteration in leukemic cells is often …
progression in acute myeloid leukemia (AML). Metabolic alteration in leukemic cells is often …
[HTML][HTML] Biological roles and therapeutic applications of IDH2 mutations in human cancer
J Guo, R Zhang, Z Yang, Z Duan, D Yin… - Frontiers in oncology, 2021 - frontiersin.org
Isocitrate dehydrogenase (IDH) is a key metabolic enzyme catalyzing the interconversion of
isocitrate to α-ketoglutarate (α-KG). Mutations in IDH lead to loss of normal enzymatic activity …
isocitrate to α-ketoglutarate (α-KG). Mutations in IDH lead to loss of normal enzymatic activity …
[HTML][HTML] ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
RB Forthun, R Hovland, C Schuster, H Puntervoll… - Scientific reports, 2019 - nature.com
Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to
predict and monitor treatment response, cancer and angiogenesis relevant mutations in …
predict and monitor treatment response, cancer and angiogenesis relevant mutations in …